This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Boiling == After mashing, the beer wort is boiled with hops (and other flavourings if used) in a large tank known as a "copper" or brew kettle – though historically the mash vessel was used and is still in some small breweries. The boiling process is where chemical reactions take place, including sterilisation of the wort to remove unwanted bacteria, releasing of hop flavours, bitterness and aroma compounds through isomerisation, stopping of enzymatic processes, precipitation of proteins, and concentration of the wort. Finally, the vapours produced during the boil volatilise off-flavours, including dimethyl sulphide precursors. The boil is conducted so that it is even and intense – a continuous "rolling boil". The boil on average lasts between 45 and 90 minutes, depending on its intensity, the hop addition schedule, and volume of water the brewer expects to evaporate. At the end of the boil, solid particles in the hopped wort are separated out, usually in a vessel called a "whirlpool".
=== Broken bone injuries in monkeys === In November 2023, the company was fined $9,000 due to the injuries of six monkeys between 2018 and 2022, mostly broken bones due to poor handling. After the injuries, four monkeys were euthanized.
== Further reading == Burgess-Cassler A, Ullah AH, Ordal GW (1982). "Purification and characterization of Bacillus subtilis methyl-accepting chemotaxis protein methyltransferase II". J. Biol. Chem. 257 (14): 8412–7. doi:10.1016/S0021-9258(18)34347-3. PMID 6806296. Kleene SJ, Toews ML, Adler J (1977). "Isolation of glutamic acid methyl ester from an Escherichia coli membrane protein involved in chemotaxis". J. Biol. Chem. 252 (10): 3214–8. doi:10.1016/S0021-9258(17)40373-5. PMID 16888. Simms SA, Stock AM, Stock JB (1987). "Purification and characterization of the S-adenosylmethionine:glutamyl methyltransferase that modifies membrane chemoreceptor proteins in bacteria". J. Biol. Chem. 262 (18): 8537–43. doi:10.1016/S0021-9258(18)47447-9. PMID 3298235. Springer WR, Koshland DE (1977). "Identification of a protein methyltransferase as the cheR gene product in the bacterial sensing system". Proc. Natl. Acad. Sci. U.S.A. 74 (2): 533–7. Bibcode:1977PNAS...74..533S. doi:10.1073/pnas.74.2.533. PMC 392324. PMID 322131.
precipitation The process of producing a separable solid phase within a liquid medium, e.g. by transforming the dissolved solute of a supersaturated solution into an insoluble solid; or the diffusion of a distinct solid phase out of a solid alloy. A reagent that causes such a reaction is called the precipitant, and the separable solid itself is the precipitate. More generally, the term may refer to the formation of any new condensed phase by changing the physical properties of a system (e.g. water vapor condensing into liquid water droplets).
==== Legislature ==== The U.S. Congress is a bicameral legislature made up of the Senate and the House of Representatives. The Senate has 100 members—two residents from each state and elected by that state's voters for a six-year term. The House of Representatives has 435 voting members, elected for a two-year term by the constituency of the congressional district in which they reside. District boundaries are generally drawn by state legislatures or redistricting commissions under state law. Every U.S. congressional district must be as nearly equal in population as practicable; each sends one representative to Congress. Election years for senators are staggered so that only one-third of them will be up for election every two years. U.S. representatives are all up for election at the same time every two years. The U.S. Congress makes federal law, declares war, has the power of the purse, and has the power of impeachment. The Senate gives advice and consent to the ratification of treaties by a two-thirds vote of senators present. One of the foremost non-legislative functions of Congress is the power to investigate and oversee the executive branch. Congressional oversight is usually delegated to committees and is facilitated by Congress' power to issue subpoenas. Much of the work of Congress is performed by a collection of committees, each appointed for a specific purpose or function. Committee membership is by tradition and statute bipartisan, but all committees are chaired by a member of the majority party, who sets the committee agenda.
Sources: en.wikipedia.org
=== Faulty paternity tests === Labcorp has been criticized over faulty paternity tests, many of which have resulted in lawsuits. The most notable case was the 2005 false accusation of Washington hairdresser Andre Chreky, who spent $200,000 and years in court proving, despite a false-positive test, that he was not the father. In the trial, it was determined that only five people at Labcorp reviewed data and made paternity determinations, including during 10 hour shifts that required making determinations every 4 minutes.
Initiation or Starting module: [F/NMT]-A-PCP- Elongation or Extending modules: -(C/Cy)-[NMT]-A-PCP-[E]- Termination or Releasing module: -(TE/R) (Order: N-terminus to C-terminus; []: optionally; (): alternatively)
==== Cognitive disengagement syndrome ==== Atomoxetine may be used to treat cognitive disengagement syndrome (CDS), as multiple randomised controlled clinical trials (RCTs) have found that it is an effective treatment. In contrast, multiple RCTs have shown that it responds poorly to the stimulant medication methylphenidate.
== Medical uses == Telisotuzumab vedotin is indicated for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
In the healthcare industry, open-source AI has been used in diagnostics, patient care, and personalized treatment options. Open-source libraries have been used for medical imaging for tasks such as tumor detection, improving the speed and accuracy of diagnostic processes. Additionally, OpenChem, an open-source library specifically geared toward chemistry and biology applications, enables the development of predictive models for drug discovery, helping researchers identify potential compounds for treatment.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.